As many of you are aware, when I joined Epizyme as CEO last quarter, we announced a number of strategic and organizational changes to more favorably impact the adoption of TAZVERIK and ultimately intend to establish it as a backbone of therapy in follicular lymphoma or FL and epithelioid sarcoma or ES. We still have plenty of work to do. We believe the changes we've made were the right ones to accelerate growth, and we have begun to see positive commercial impact.